CTLA4 and melanoma: Engeland et al. generated attenuated Measles virus (MV) vectors encoding antibodies against both CTLA-4 and PD-L1 and found that the combination group demonstrated higher rates of complete tumor remission (>80%) than control vectors encoding anti-CTLA-4 and anti-PD-L1 in murine models of malignant melanoma (61).